Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The conversation is about the best microneedling depth and frequency for hair loss treatment. The user recommends 1.5mm once a week.

The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.

The conversation is about exploring additional hair loss treatments, with suggestions including topical melatonin, caffeine-based shampoos, redensyl, copper-peptides, pumpkin seed oil, saw palmetto, ketoconazole shampoo, and fluridil. Caution is advised against using products from AliExpress and Temu due to potential safety concerns.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.

The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about a user offering an unopened bottle of KX-826 (0.5%) for hair loss treatment, stating it works well for them. They are selling it at cost without seeking profit.

A new product, Minoxidil booster, which enhances sulfotransferase enzyme activity in the scalp, is now available. The user has started using this product, applied before Minoxidil, to improve their hair loss treatment results.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.

The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

RU58841 is used by some for hair loss, with mixed results; one user reported success with no side effects, while another experienced lung and heart issues. RU58841 is often sourced from third-party vendors and used alongside treatments like dutasteride and minoxidil.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.